Application of strychnine in treating amyotrophic lateral sclerosis

By using strychnine as a treatment for ALS and controlling the dosage within a safe range, the shortcomings of existing ALS treatments have been overcome, achieving the effects of delaying the onset of the disease, prolonging survival time, and improving limb function.

CN118976026AInactive Publication Date: 2024-11-19ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410974825.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a lack of effective treatments for amyotrophic lateral sclerosis (ALS) in the current technology, and existing drugs such as riluzole and edaravone are expensive and have many side effects. The use of the traditional Chinese medicine nux vomica is limited due to its high toxicity. How to reduce its toxicity and increase its efficacy has become the key.

Method used

Strychnine is used as a drug to treat ALS. It is administered in the form of tablets, capsules, etc., with the dosage controlled within a safe range. It is used to delay the onset of ALS, prolong survival time, and improve limb function.

Benefits of technology

Strychnine significantly delays the onset of ALS, prolongs survival time, improves limb grip strength, and slows the decline in limb extension ability, providing a new treatment option for ALS.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976026A_ABST
    Figure CN118976026A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedicine, in particular to the technical field of application of strychnine in treatment of amyotrophic lateral sclerosis. The invention discloses application of strychnine in treatment of amyotrophic lateral sclerosis. The strychnine can delay the onset time of amyotrophic lateral sclerosis, prolong the survival time, delay weakening of limb stretching ability and improve limb holding power.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the technical field of biomedicine, in particular to the technical field of application of strychnine in treating amyotrophic lateral sclerosis. [Background technology]

[0002] Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disease that mainly affects motor neurons. It is the main type of motor neuron disease (MND), accounting for 80%-90% of MND, and is even considered to be the final development destination of other MND subtypes. ALS is a rare disease with a global incidence of about 3 / 100,000, an average age of onset of 55-60 years, an average survival of about 3-5 years, and most patients die of respiratory muscle failure. ALS is divided into familial and sporadic types. The incidence of familial ALS accounts for about 5%-10% of the total ALS, and the onset time is often earlier than that of sporadic ALS. 20-25% of familial ALS and 3% of sporadic ALS are related to superoxide dismutase 1 (SOD1) gene mutations.

[0003] ALS is a refractory disease in the nervous system, characterized by the chronic progressive degeneration of the anterior horn of the spinal cord, the posterior motor nuclei of the brainstem and the pyramidal tract, and the involvement of both upper and lower motor neurons. Its pathogenesis has not yet been determined. At present, the treatment of ALS patients is mainly symptomatic, and there is no effective treatment. The US Food and Drug Administration (FDA) has approved the main drugs for ALS patients, Riluzole and Edaravone, which play a role in delaying the progression of the disease to a certain extent, but these drugs are expensive and have many side effects. It is difficult to promote them in clinical practice. The side effects of long-term use of Western medicine have prompted people to try to examine traditional therapies from a new perspective, hoping to find new ways to treat them.

[0004] Traditional Chinese medicine has the effect of multi-pathway and multi-target comprehensive treatment, and shows unique advantages in disease treatment. The traditional Chinese medicine Strychnos nux vomica is the dried mature seeds of the plant Strychnos nux vomica of the Loganaceae family. It has the effects of dredging collaterals and relieving pain, dispersing nodules and reducing swelling. Ancient and modern doctors have accumulated rich experience in its clinical application. Modern pharmacological research and clinical practice have shown that Strychnos nux vomica has a wide range of pharmacological activities, such as anti-inflammatory, analgesic, anticoagulant and other pharmacological effects. It can also promote fracture healing and treat bone hyperplasia and other orthopedic diseases. However, Strychnos nux vomica is a highly toxic drug, and its clinical application is limited by problems such as a narrow therapeutic window. The 2020 edition of the "Chinese Pharmacopoeia" stipulates that the dosage of Strychnos nux vomica is 0.3-0.6g. Literature reports that Strychnos nux vomica will have toxic reactions when it exceeds 0.9g in clinical applications, and oral administration of 7g of Strychnos nux vomica crude drug can be lethal, and the onset is acute. Therefore, how to achieve the purpose of "reducing toxicity and increasing efficacy" through various means is an important direction of current research, and the key to solving this problem is to control the "amount" of its toxic components. Strychnine, the active ingredient of Strychnine, has unique advantages in this regard. Compared with Strychnine, Strychnine has the characteristics of low toxicity, long half-life and high bioavailability. Domestic and foreign scholars have shown that Strychnine has significant analgesic, anti-inflammatory, anti-tumor and central nervous system stimulant effects, but the potential efficacy of Strychnine in the treatment of ALS has not yet been studied. [Summary of the invention]

[0005] The purpose of the present invention is to solve the problems in the prior art and to propose the use of strychnine in the treatment of amyotrophic lateral sclerosis, which can delay the onset of amyotrophic lateral sclerosis, prolong the survival time, delay the weakening of limb extension ability, and improve limb grip.

[0006] To achieve the above object, the present invention proposes the use of strychnine in treating amyotrophic lateral sclerosis.

[0007] Preferably, the amyotrophic lateral sclerosis is a progressive, fatal neurodegenerative disease that primarily affects motor neurons.

[0008] Preferably, the amyotrophic lateral sclerosis is the main type of motor neuron disease, accounting for 80%-90% of motor neuron disease.

[0009] Preferably, the amyotrophic lateral sclerosis is mammalian amyotrophic lateral sclerosis.

[0010] Preferably, the treatment is to delay the onset of ALS and prolong the survival time.

[0011] Preferably, the treatment is to delay the reduction of the ability to extend the limbs.

[0012] Preferably, the treatment is improving limb grip.

[0013] Preferably, the strychnine is in the form of a preparation, including tablets, capsules, granules, powders, pills, lozenges, powders, solutions, syrups, suspensions, emulsions or elixirs.

[0014] Preferably, the strychnine is used simultaneously with other drugs for treating amyotrophic lateral sclerosis.

[0015] Beneficial effects of the present invention: The present invention provides an application of strychnine in the treatment of amyotrophic lateral sclerosis, discovers a new use of strychnine, expands the application of strychnine in medicine, and provides a new technical means for the treatment of amyotrophic lateral sclerosis. Strychnine can delay the onset of amyotrophic lateral sclerosis, prolong the survival time, delay the weakening of limb extension ability, and improve limb grip.

[0016] The features and advantages of the present invention will be described in detail through embodiments in conjunction with the accompanying drawings.

Brief Description of the Drawings

[0017] Figure 1 This is a graph showing changes in the body weight of mice using strychnine in the present invention in the treatment of amyotrophic lateral sclerosis;

[0018] Figure 2 This is a graph of the onset time of mice using strychnine in the present invention in treating amyotrophic lateral sclerosis;

[0019] Figure 3 is a graph of mouse survival time of the application of strychnine in the present invention in treating amyotrophic lateral sclerosis;

[0020] Figure 4 This is a diagram showing the extension of the hind limbs of mice using strychnine in the present invention for treating amyotrophic lateral sclerosis as the disease progresses;

[0021] Figure 5 This is a graph showing changes in the gripping force of mice in the application of strychnine in the present invention in the treatment of amyotrophic lateral sclerosis;

[0022] Figure 6 This is a graph showing the maximum motor capacity of mice using strychnine in the present invention in treating amyotrophic lateral sclerosis. [Specific implementation method]

[0023] Selection of hSOD1 G93A Transgenic mice are used as ALS model mice. Because the 93rd alanine residue of hSOD1 is replaced by glycine (G93A), superoxide radicals cannot be eliminated from the body, reactive oxygen species (ROS) are excessively produced, and the body suffers oxidative damage. This is a classic model for studying ALS. This classic model is used to evaluate the effect of strychnine in ALS.

[0024] According to the previous acute toxicity experiment of strychnine, the drug dose was less than or equal to 40 mg / kg, and no mice died and showed no symptoms of poisoning, which was within the safe dose range. Considering that long-term oral gavage toxicity will accumulate, in order to ensure the safety of long-term oral gavage mice, 10 mg / kg was determined to be used for the efficacy test of strychnine on ALS.

[0025] Treatment of ALS animal model hSOD1 by intragastric administration of 10 mg / kg strychnine G93A Transgenic mice were used to detect the motor function of the model mice and record the onset time and survival period of the mice to evaluate the efficacy of strychnine, providing preliminary experimental basis for the efficacy and mechanism of strychnine in treating ALS animal models.

[0026] 2.1 Animal grouping and drug administration

[0027] Select 8-week-old hSOD1 G93A A total of 10 transgenic mice were randomly divided into a model group and a treatment group according to the number, with 5 hSOD1 in each group. G93A Transgenic mice, 5 wild-type mice from the same litter were assigned as the normal control group; model group hSOD1 G93A Transgenic mice were intragastrically administered with 0.9% saline (10 mg / kg); hSOD1 G93A The transgenic mice were gavaged with 10 mg / kg strychnine; the wild-type mice in the normal control group were gavaged with 10 mg / kg 0.9% saline.

[0028] 2.2 Weight changes

[0029] The body weight of mice in each group was measured and recorded weekly using an electronic scale.

[0030] 2.3 Onset time and survival period

[0031] 2.3.1 Onset time

[0032] The model mice were evaluated daily using the Weydt 4-point method in Table 2-1, and the initial time when the Weydt score was <4 points was recorded as the onset time.

[0033] 2.3.2 Lifetime

[0034] The mice were turned over to the supine position. If they could not turn back to the prone position within 30 s, the Weydt score of 0 was recorded as the time of death.

[0035] Table 2-1 Weydt 4-point scoring table

[0036]

[0037] 2.4 Motor function assessment

[0038] 2.4.1 Tail suspension test

[0039] Suspend the mouse's tail, observe the extension of its hind limbs and flexion of its waist, and score according to Table 2-2.

[0040] Table 2-2 Scoring table for tail suspension test

[0041]

[0042] 2.4.2 Grip test

[0043] Use a grip strength meter to measure the grip strength of mice. Place the mouse gently on the grip board, then grab the mouse's tail and gently and slowly pull it backward horizontally. After the mouse completely releases the grip board, the instrument automatically records the mouse's maximum grip strength value. Record this value. Measure each mouse 3 times and take the average value as its grip strength value.

[0044] 2.4.3 Flat Treadmill for Mice

[0045] (1) Maximum exercise capacity test: At the beginning of the test, the speed was set at 12 m / min, and then the speed was increased by 1 m / min every 3 minutes until the mouse could no longer keep running and fell. At this time, the speed, time, and distance before falling were recorded.

[0046] (2) Endurance test: Set a fixed but challenging speed for mice (70% of the speed recorded in the maximum exercise capacity test; based on previous experimental data, the speed was determined to be 15 m / min), and then record the time and distance required for the mice to maintain exercise until fatigue (unable to keep running and falling).

[0047] 4.1 hSOD1 after onset G93A Transgenic mice lose weight

[0048] The body weight of model mice was measured at 7 weeks of age. From the 7th to the 14th week, the body weight of mice in the control group, model group and treatment group increased slowly, and there was no significant difference among the groups. From the 15th week, the body weight of mice in the model group showed an overall trend of weight loss, while the body weight of mice in the control group continued to increase slowly. There was no statistically significant difference between the treatment group and the model group. hSOD1 G93A The difference between the transgenic mouse model group and the control group was statistically significant (P<0.0001) (see Figure 1 ).

[0049] 4.2 Onset time and survival observation

[0050] 4.2.1 Strychnine can delay hSOD1 G93A Disease onset time of transgenic mice

[0051] The average onset time of mice in the model group was 188 days, and the onset time of mice in the 10 mg / kg strychnine treatment group was about 206 days. The P value of the comparison between the model group and the treatment group was 0.0328, and the onset time had significant statistical significance (see Figure 2 ).

[0052] 4.2.2 Strychnine can prolong hSOD1 G93A Survival time of transgenic mice

[0053] So far, 4 mice in the model group died, and 1 mouse in the treatment group died. The average survival time of mice in the model group was 200 days, and the survival time of mice in the 10 mg / kg strychnine treatment group was about 222 days. The P value of the comparison between the model group and the treatment group was 0.0145, and the onset time was statistically significant (see Figure 3 ).

[0054] 4.3 Motor function assessment

[0055] 4.3.1 Tail suspension test

[0056] hSOD1 G93A As the disease progresses, the ability of the hind limbs to extend gradually weakens in the transgenic mouse model group (see Figure 4 ). At 6 months of age, the tail suspension test was performed, and the mice's tails were suspended. The hind limb extension ability of the mice treated with strychnine was stronger than that of the model group.

[0057] Figure 4 A in the middle is hSOD1 G93A Hind limb extension of transgenic mouse model group mice before disease onset, B is hSOD1 G93A Hind limb extension of transgenic mouse model group mice at the initial onset of disease, C is hSOD1 G93A Hind limb extension of mice in the transgenic mouse model group in the late stage of the disease.

[0058] 4.3.2 Grip test

[0059] At 22 weeks, the grasping strength of mice in each group was tested, and there was no significant difference in the grasping strength of mice in each group. At 25 weeks, the grasping strength of mice in the model group was significantly lower than that in the blank group (P<0.0001), while the grasping strength of mice in the strychnine treatment group was higher than that in the model group (P<0.05). G93A The grasping force of the transgenic mice model group showed a downward trend (see Figure 5 ).

[0060] 4.3.3 Flat Treadmill for Mice

[0061] The mice were tested for maximum exercise capacity at 19 weeks of age. G93AThe maximum exercise capacity of the transgenic mice model group was weak and gradually weakened with the progression of the disease. The maximum exercise capacity of the mice in the model group decreased significantly at 22 weeks (5.5 months old), and there was a significant difference from the control group at 23 weeks (5.75 months old). At the same time, the mice were tested for endurance using a treadmill. The results were consistent with the maximum exercise capacity test. Compared with the control group, hSOD1 G93A The endurance of the transgenic mice model group was weak and gradually weakened with the progression of the disease. At 22 weeks (5.5 months old), hSOD1 G93A The endurance time and distance of the transgenic mice model group decreased significantly, and there was a significant difference between the mice in the control group at 23 weeks (5.75 months old) (see Figure 6 ).

[0062] Figure 6 AC in hSOD1 G93A The maximum movement speed, time and distance of mice in the transgenic mouse model group, DE was hSOD1 G93A Endurance training of transgenic mouse model group mice.

[0063] In this study, hSOD1 was selected G93A Transgenic mice were used as ALS model mice. In the survival rate experiment of ALS mice, the onset time and progressive symptoms of ALS mice were observed and recorded. G93A Transgenic mice begin to develop symptoms around 23 weeks of age (161 days old). After onset, the mice will experience hind limb tremors during tail suspension, and as the disease worsens, hSOD1 G93A Transgenic mice will have weak hind limb extension, abnormal gait, and dragging hind limbs. In the late stage of the disease, the mice will have complete paralysis of their hind limbs, atrophy of the body, arched spine, eating disorders, and rapid weight loss.

[0064] Decreased body weight or body mass index (BMI) is an independent prognostic factor for ALS. The study began recording the weight of mice at 7 weeks of age, when hSOD1 G93A The transgenic mice showed no symptoms of the disease, and their body weight was not significantly different from that of the control mice. G93A The transgenic mice began to lose weight at around 12 weeks of age (3 months old), and showed significant differences from the control group at 21 weeks of age (5.25 months old), but strychnine treatment had no obvious effect on improving the weight of mice.

[0065] hSOD1 G93ATransgenic mice develop the disease at around 5.5 months of age. As the disease progresses, their motor ability gradually decreases, and significantly decreases at the peak of the disease. 10 mg / kg of strychnine was administered to mice for preventive treatment 1 month before the onset of the disease. Analysis of behavioral experimental data such as grip strength, tail suspension, and treadmill showed that compared with the model group, the grip strength of mice improved after treatment with 10 mg / kg strychnine, which significantly improved the grip strength of ALS mice. However, the therapeutic effect of strychnine on the motor ability of mice was not significant.

[0066] In summary, 10 mg / kg strychnine significantly delayed the onset of ALS mice, prolonged the survival time of mice, and significantly improved the grip strength of mice.

[0067] The above embodiments are intended to illustrate the present invention, not to limit the present invention. Any solution that is a simple transformation of the present invention belongs to the protection scope of the present invention.

Claims

1. Application of strychnine in the treatment of amyotrophic lateral sclerosis.

2. The use according to claim 1, characterized in that: Amyotrophic lateral sclerosis is a progressive, fatal neurodegenerative disease that primarily affects motor neurons.

3. The use according to claim 1, characterized in that: Amyotrophic lateral sclerosis is the main type of motor neuron disease, accounting for 80%-90% of motor neuron diseases.

4. The use according to claim 1, characterized in that: The amyotrophic lateral sclerosis is amyotrophic lateral sclerosis in mammals.

5. The use according to claim 1, characterized in that: The treatment delays the onset of amyotrophic lateral sclerosis and prolongs survival time.

6. The use according to claim 1, characterized in that: The treatment is to delay the decrease in the ability to extend the limbs.

7. The use according to claim 1, characterized in that: The treatment is to improve limb grip.

8. The use according to claim 1, characterized in that: The strychnine is in the form of a preparation, including tablets, capsules, granules, powders, pills, lozenges, powders, solutions, syrups, suspensions, emulsions or elixirs.

9. The use according to claim 1, characterized in that: The strychnine is used simultaneously with other drugs for treating amyotrophic lateral sclerosis.

Citation Information

Patent Citations

  • Strychnos alkaloid vesicle and preparation method thereof

    CN101797239A

  • Treating neuromuscular or neurologic disease through reducing gabaergic and / or glycinergic inhibitory neurotransmitter overstimulation

    WO2017065602A1